Samsung Biologics partners with Dinona for potential COVID-19 treatment
Singapore, Oct. 21 -- Samsung Biologics has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.
Under this agreement, South Korean firms Samsung and Dinona will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.
Since its inception, the Samsung Biologics CDO business has been growing at a rapid pace with near 60 contracts signed in just two years. The business segment continues to expand its market reach through a cumulative track record of various biologics products beyond monoclonal antibodies and by ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.